MedTrace Logo

Effect of ADT in Chinese Male With Prostate Cancer

NCT04341324 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 60

Last updated 2020-04-10

No results posted yet for this study

Summary

Many prostate cancer patients required the use of androgen deprivation therapy (ADT) for the control of disease.

In this study, the investigators aim at assessing the different in various parameters between PCa patients received ADT and those without ADT.

60 patients diagnosed with PCa and planned for hormonal therapy will be recruited for study (active arm) and 30 PCa patients that do not planned to receive hormonal therapy (based on the clinical assessment by the investigators) will be recruited as control arm.

After written consent obtained from study subject, a series of investigation will be arranged to assess the following aspect of the subjects before the commenced of ADT:

* General condition - symptoms, general health,
* Body composition - BMI and body composition
* Mental state assessment by Mini-Mental State Examination (MMSE)
* Blood for fasting lipid, sugar, hsCRP and other hormones (about 15cc)
* Cardiovascular status - BP, Ankle-brachial index (ABI), Arterial stiffness, ECG,
* Bone status - bone mineral density by dual-energy X-ray absorptiometry (DEXA) scan

The assessment of general condition, body composition, blood parameter and cardiovascular status will be performed every 26weeks +/- 1 weeks for two years. Bone density measurement will be performed every 52 weeks +/- 2 weeks.

Appropriate medical referral will be made if subject was found to have abnormal metabolic or cardiovascular parameters.

Conditions

Interventions

OTHER

It is an observational study.

Sponsors & Collaborators

  • Chinese University of Hong Kong

    lead OTHER

Principal Investigators

  • Chi Fai NG, MD · Chinese University of Hong Kong

Eligibility

Min Age
18 Years
Max Age
100 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-07-14
Primary Completion
2019-12-04
Completion
2019-12-04

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04341324 on ClinicalTrials.gov